Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy

被引:68
作者
Broomfield, S
Currie, A
van der Most, RG
Brown, M
van Bruggen, I
Robinson, BWS
Lake, RA
机构
[1] Univ Western Australia, Sch Med & Pharmacol, Sir Charles Gairdner Hosp, Perth, WA 6009, Australia
[2] Univ Western Australia, Western Australia Inst Med Res, Sir Charles Gairdner Hosp, Perth, WA 6009, Australia
关键词
D O I
10.1158/0008-5472.CAN-05-0328
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Resection alone is rarely curative for advanced tumors, but the outcome generally improves with adjuvant therapy. We have previously shown that a combination of traditional chemotherapy (gemcitabine) and immunotherapy (anti-CD40/FGK-45) without surgery is synergistic and can lead to long-term cure when applied to small tumors. Such cured animals have immunologic memory and are protected from rechallenge. Here we investigate the effectiveness of combination chemotherapy and immunotherapy after partial or complete surgical debulking of large tumors. We found that complete resection followed by combination chemotherapy/immunotherapy led to a high rate of cure (>80%) but failed to induce a long-term, tumor-specific memory. Partial debulking followed by combination therapy elicited the same proportion of cured animals but in contrast to complete resection, a memory response was invoked. We postulate that chemotherapy induced apoptosis of the residual tumor cells following incomplete resection is absolutely required for the induction of long-term immunologic memory.
引用
收藏
页码:7580 / 7584
页数:5
相关论文
共 19 条
[1]   Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival [J].
Adams, AB ;
Shirasugi, N ;
Jones, TR ;
Durham, MM ;
Strobert, EA ;
Cowan, S ;
Rees, P ;
Hendrix, R ;
Price, K ;
Kenyon, NS ;
Hagerty, D ;
Townsend, R ;
Hollenbaugh, D ;
Pearson, TC ;
Larsen, CP .
JOURNAL OF IMMUNOLOGY, 2005, 174 (01) :542-550
[2]   Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease [J].
Danna, EA ;
Sinha, P ;
Gilbert, M ;
Clements, VK ;
Pulaski, BA ;
Ostrand-Rosenberg, S .
CANCER RESEARCH, 2004, 64 (06) :2205-2211
[3]   ESTABLISHMENT OF A MURINE MODEL OF MALIGNANT MESOTHELIOMA [J].
DAVIS, MR ;
MANNING, LS ;
WHITAKER, D ;
GARLEPP, MJ ;
ROBINSON, BWS .
INTERNATIONAL JOURNAL OF CANCER, 1992, 52 (06) :881-886
[4]   The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment [J].
den Boer, AT ;
van Mierlo, GJD ;
Fransen, MF ;
Melief, CJM ;
Offringa, R ;
Toes, REM .
JOURNAL OF IMMUNOLOGY, 2004, 172 (10) :6074-6079
[5]   ON CONCOMITANT IMMUNITY IN TUMOUR-BEARING HAMSTERS [J].
GERSHON, RK ;
CARTER, RL ;
KONDO, K .
NATURE, 1967, 213 (5077) :674-&
[6]   Opinion - The promise of cancer vaccines [J].
Gilboa, E .
NATURE REVIEWS CANCER, 2004, 4 (05) :401-411
[7]   Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells [J].
Kaech, SM ;
Tan, JT ;
Wherry, EJ ;
Konieczny, BT ;
Surh, CD ;
Ahmed, R .
NATURE IMMUNOLOGY, 2003, 4 (12) :1191-1198
[8]   Immunology - Licence to kill [J].
Lanzavecchia, A .
NATURE, 1998, 393 (6684) :413-414
[9]  
Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6
[10]  
Marzo AL, 1999, CANCER RES, V59, P1071